Revelation Biosciences (REVB) said Thursday it is on track to hold a meeting with the US Food and Drug Administration later this year following the submission and acceptance of its end-of-phase 1 meeting package to the regulator.
The meeting will establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments